Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models

被引:13
|
作者
Liu, Lan-Xiang [1 ]
Du, Dan [1 ]
Wang, Zhan-Qiu [1 ]
Fang, Yuan [1 ]
Zheng, Tao [1 ]
Dong, Yan-Chao [2 ]
Shi, Qing-Lei [3 ]
Zhao, Min [4 ]
Xiao, Fang [4 ]
Du, Juan [5 ]
机构
[1] Qinhuangdao Municipal 1 Hosp, Dept Magnet Resonance Imaging, Qinhuangdao, Hebei, Peoples R China
[2] Qinhuangdao Municipal 1 Hosp, Dept Intervent, Qinhuangdao, Hebei, Peoples R China
[3] Siemens Ltd, Beijing, Peoples R China
[4] Qinhuangdao Municipal 1 Hosp, Dept Pathol, Qinhuangdao, Hebei, Peoples R China
[5] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
关键词
nerve regeneration; fractional anisotropy; T2*; rotenone; 6-hydroxydopamine; Parkinson's disease; magnetic resonance imaging; diffusion tensor imaging; dopaminergic neurons; neural regeneration; WHITE-MATTER CHANGES; SUBSTANTIA-NIGRA; COMPLEX-I; DEGENERATION; MECHANISMS; DEPOSITION; TOXICITY; SYSTEM;
D O I
10.4103/1673-5374.235076
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson's disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson's disease were generated by injection of 3 mu g rotenone or 10 mu g 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2* values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2* values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson's disease over long periods.
引用
收藏
页码:1276 / 1280
页数:5
相关论文
共 50 条
  • [21] Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson's disease
    Li, Jia
    Sun, Yajuan
    Chen, Jiajun
    GENES & GENETIC SYSTEMS, 2019, 94 (02) : 61 - 69
  • [22] The reaction of nitric oxide with 6-hydroxydopamine:: Implications for Parkinson's disease
    Riobó, NA
    Schöpfer, FJ
    Boveris, AD
    Cadenas, E
    Poderoso, JJ
    FREE RADICAL BIOLOGY AND MEDICINE, 2002, 32 (02) : 115 - 121
  • [23] Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease
    Sikora, Joanna
    Kieffer, Brigitte L.
    Paoletti, Pierre
    Ouagazzal, Abdel-Mouttalib
    NEUROBIOLOGY OF DISEASE, 2020, 134
  • [24] Neuroprotection by safinamide in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease
    Sadeghian, M.
    Roach, A.
    Smith, K. J.
    MOVEMENT DISORDERS, 2011, 26 : S286 - S286
  • [25] Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease
    Glajch, Kelly E.
    Fleming, Sheila M.
    Surmeier, D. James
    Osten, Pavel
    BEHAVIOURAL BRAIN RESEARCH, 2012, 230 (02) : 309 - 316
  • [26] Exercise-Induced Neuroprotection in the 6-Hydroxydopamine Parkinson’s Disease Model
    Zeinab Rezaee
    Sayed Mohammad Marandi
    Hojjatallah Alaei
    Fahimeh Esfarjani
    Neurotoxicity Research, 2020, 38 : 850 - 858
  • [27] Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model
    Cannon, JR
    Keep, RF
    Hua, Y
    Richardson, RJ
    Schallert, T
    Xi, GH
    NEUROSCIENCE LETTERS, 2005, 373 (03) : 189 - 194
  • [28] Characterization of the gastrointestinal dysfunction in the 6-hydroxydopamine rat model of Parkinson's disease
    Chai, X.
    Diwakarla, S.
    Pustovit, R.
    McQuade, R.
    Di Natale, M.
    Ermine, C.
    Parish, C.
    Finkelstein, D.
    Furness, J.
    MOVEMENT DISORDERS, 2019, 34 : S629 - S629
  • [29] Exercise-Induced Neuroprotection in the 6-Hydroxydopamine Parkinson's Disease Model
    Rezaee, Zeinab
    Marandi, Sayed Mohammad
    Alaei, Hojjatallah
    Esfarjani, Fahimeh
    NEUROTOXICITY RESEARCH, 2020, 38 (04) : 850 - 858
  • [30] GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease
    Smith, Michael P.
    Cass, Wayne A.
    NEUROSCIENCE LETTERS, 2007, 412 (03) : 259 - 263